Bruce Cahill v. Paul Edalat

Court of Appeals for the Ninth Circuit·Decided July 8, 2021·No. 17-56826·Unpublished

Opinion

NOT FOR PUBLICATION FILED UNITED STATES COURT OF APPEALS JUL 8 2021 MOLLY C. DWYER, CLERK

U.S. COURT OF APPEALS

FOR THE NINTH CIRCUIT

BRUCE CAHILL; et al., Nos. 17-56826, 17-56894, 18-

55171

Appellees/Cross-Appellants, D.C. No. 8:16-cv-00686-AG-DFM v.

PAUL EDALAT; OLIVIA MEMORANDUM* KARPINSKI,

Appellants/Cross-Appellees.

Appeal from the United States District Court for the Central District of California Andrew Guilford, District Judge, Presiding

Argued and Submitted May 3, 2021 Pasadena, California

Before: OWENS and LEE, Circuit Judges, and SIMON **, District Judge.

Pharma Pak Inc., a marijuana-related venture, faltered, leading to this legal fracas in which the company’s investors and employees sued each other on a wide variety of claims. Bruce Cahill, Ron Franco, and Greg Cullen brought claims of

*

This disposition is not appropriate for publication and is not precedent except as provided by Ninth Circuit Rule 36-3.

** The Honorable Michael H. Simon, United States District Judge for the District of Oregon, sitting by designation.

fraud and defamation against Paul Edalat and Olivia Karpinski. In response, Edalat and Karpinski asserted counterclaims against Cahill — Edalat for breach of fiduciary duty, and Karpinski for sexual harassment and other employment-related claims. Both sides won some and lost some at trial, and both sides now appeal various aspects of the district court’s trial and post-trial rulings. As the parties are familiar with the facts, we do not recount them here. We have jurisdiction under 28 U.S.C. § 1291, and we affirm.

1. The district court did not err in instructing the jury on Edalat’s breach of fiduciary duty claim. In our view, the jury instruction accurately reflects the legal rules set out in California Corporations Code § 310(a), which governs corporate transactions involving interested shareholders. “Section 310(a) provides that a vote on the matter is not void or voidable because the interested director is present at the board meeting if one of three alternatives are satisfied.” Sammis v. Stafford, 56 Cal. Rptr. 2d 589, 592 (Ct. App. 1996). The first two alternatives involve situations where a disinterested majority vote is still possible, whether by barring the interested shareholder from voting, or by not counting the interested shareholder’s vote. The third alternative involves situations where a transaction is “based on a vote by the interested director.” Id. at 594. Under those circumstances, the interested shareholder bears the burden of proving that the transaction was just and reasonable. Cal. Corp. Code § 310(a)(3).

Here, the jury instruction captures all three alternatives. First, the instruction provides that “a sale or other transfer of the assets of a Pharma Pak Inc. must have been approved by a majority of the shareholders of Pharma Pak Inc.” Then, in the case of an interested transaction, the instruction says that one of three additional requirements, including the “just and reasonable” requirement, “must have also been met” on top of the baseline majority approval requirement. Finally, the jury instruction states that if there was no “proper authorization” for the transaction, then there was a breach of fiduciary duty. Cahill argues that the jury instruction directed the jury to find in favor of Edalat as long as there was no “authorization” for the asset transfer, without considering whether the transaction was just and reasonable. We read the phrase “authorization” to mean that one of the three alternatives listed immediately above in the instructions — including the “just and reasonable” requirement — was satisfied. In other words, the jury could not have found a breach of fiduciary duty without first considering whether the transaction was just and reasonable. We therefore reject Cahill’s jury instruction challenge on cross-appeal.

2. The district did not err when it entered judgment on the fiduciary duty claim in favor of Edalat in his individual shareholder capacity instead of in favor of Pharma Pak as a corporation. As a threshold matter, Cahill did not waive his objection to the entry of judgment in favor of Edalat in his direct shareholder capacity. It was not clear from the pre-trial filings that Edalat intended to submit

only a direct, not a derivative, claim to the jury, and when it did become clear, Cahill timely filed an objection to the proposed judgment form.

Turning to the substance of the argument, Cahill asserts on cross-appeal that the fiduciary duty claim in this case could only have been brought as a derivative claim on behalf of the corporation, not as a direct claim on behalf of Edalat in his individual capacity. In general, “an action is derivative if the gravamen of the complaint is injury to the corporation, or to the whole body of its stock or property without any severance of distribution among individual holders, or if it seeks to recover assets for the corporation or to prevent the dissipation of its assets.” Schuster v. Gardner, 25 Cal. Rptr. 3d 468, 473 (Ct. App. 2005) (cleaned up). In contrast, an action can be brought in an individual capacity “only where it appears that the injury resulted from the violation of some special duty owed the stockholder by the wrongdoer and having its origin in circumstances independent of the plaintiff’s status as a shareholder.” Nelson v. Anderson, 84 Cal. Rptr. 2d 753, 761 (Ct. App. 1999) (cleaned up).

In this case, the jury awarded Edalat $250,000 in damages on the fiduciary duty claim. Based on the trial transcript, we are convinced that this award was only meant to compensate Edalat for his individual harms. It would be one thing, for instance, if the $250,000 was solely meant to compensate Edalat for the devaluation of his Pharma Pak stock; in that case, Edalat would be in the same position as every

other Pharma Pak shareholder because all Pharma Pak stock would have been devalued as a result of the unauthorized asset transfer.1 See Everest Invs. 8 v. McNeil Partners, 8 Cal. Rptr. 3d 31, 41-42 (Ct. App. 2003); Sax v. World Wide Press, Inc., 809 F.2d 610, 614 (9th Cir. 1987).

But here, the trial transcript suggests that the only realistic basis for the $250,000 award was the amount of money that Cahill personally owed Edalat in his individual capacity. Specifically, when Cahill bought stock in Pharma Pak, he bought the stock directly from Edalat, paying Edalat $500,000. Half of that sum went directly to Edalat, while the other half went into the company to satisfy Edalat’s capital call. But due to the unauthorized asset transfer, Edalat never saw the benefit of the latter $250,000. That loss is distinct from the loss suffered by the company as a whole, because it is more akin to the breach of a contractual obligation between Cahill and Edalat, as opposed to being merely incidental to the devaluation of the

1 During closing arguments, Edalat’s counsel asked the jury to award Edalat $6,320,000 in damages for the breach of fiduciary duty by Cahill. That number was taken directly from the value of the assets transferred from Pharma Pak to Life Tech Global: Life Tech Global was (allegedly) worth $20 million, which meant the transferred Pharma Pak assets were worth $20 million, and because Edalat owned 31.6 percent of Pharma Pak, Edalat was thus entitled to 31.6 percent of $20 million, or $6,320,000. If the jury did indeed award Edalat the lost value of his shares, then this claim would more closely resemble a derivative claim. But ultimately, we see nothing in the record to suggest that the jury’s $250,000 award was in fact tied to the supposedly lost value of Edalat’s ownership share in Pharma Pak. Indeed, the jury was not required to accept Edalat’s proposed $6,320,000 valuation of his ownership share in Pharma Pak.

company as a whole. For that reason, we hold that the district court did not err in entering judgment in favor of Edalat in his individual capacity.

Free access — add to your briefcase to read the full text and ask questions with AI

Bruce Cahill v. Paul Edalat, (9th Cir. 2021).

Bruce Cahill v. Paul Edalat (Bruce Cahill v. Paul Edalat) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

New York Times Co. v. Sullivan
376 U.S. 254 (Supreme Court, 1964)
Rosenblatt v. Baer
383 U.S. 75 (Supreme Court, 1966)
Sax v. World Wide Press, Inc.
809 F.2d 610 (Ninth Circuit, 1987)
Marbled Murrelet v. Babbitt
83 F.3d 1060 (Ninth Circuit, 1996)
Tarla Makaeff v. Trump University, Llc
715 F.3d 254 (Ninth Circuit, 2013)
GHK Associates v. Mayer Group, Inc.
224 Cal. App. 3d 856 (California Court of Appeal, 1990)
Schuster v. Gardner
25 Cal. Rptr. 3d 468 (California Court of Appeal, 2005)
Nelson v. Anderson
84 Cal. Rptr. 2d 753 (California Court of Appeal, 1999)
Everest Investors 8 v. McNeil Partners
8 Cal. Rptr. 3d 31 (California Court of Appeal, 2003)
Sammis v. Stafford
48 Cal. App. 4th 1935 (California Court of Appeal, 1996)
Chavez v. City of Los Angeles
224 P.3d 41 (California Supreme Court, 2010)
Cion Peralta v. T. Dillard
744 F.3d 1076 (Ninth Circuit, 2014)
Meister v. Mensinger
230 Cal. App. 4th 381 (California Court of Appeal, 2014)
Jones v. Las Vegas Metropolitan Police Department
873 F.3d 1123 (Ninth Circuit, 2017)
Tan Lam v. City of Los Banos
976 F.3d 986 (Ninth Circuit, 2020)